Showing results (91-100 of 157) with videos related to
Sort By:
Pageof 16
Cell Reports|July 13, 2022
Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancersKezhong Chen, Airong Yang, David P Carbone, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases AnalysisMyung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomasMiguel Taron, Yukito Ichinose, Rafael Rosell, et al.Cancer|April 16, 2013
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsAndrew J Weickhardt, Robert C Doebele, W Thomas Purcell, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland ChinaYi-Long Wu, Wen-Zhao Zhong, Long-Yun Li, et al.Critical Reviews in Oncology/Hematology|May 20, 2020
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, et al.British Journal of Cancer|December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.Molecular Cancer|July 19, 2017
FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancerShucai Yang, Yi Liu, Ming-Yue Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studiesYi-Long Wu, Victor Lee, Chong-Kin Liam, et al.Pageof 16